X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Gretta Stone

Gretta Stone Gretta Stone is a former deputy vice president of policy & research at PhRMA.

Recent Posts

New report details the setbacks and challenges to Alzheimer’s research

By Gretta Stone  |    September 12, 2018
Illustrating the challenges of developing medicines to fight Alzheimer’s disease, a new analysis found that between 1998 and 2017, there were 146 unsuccessful medicines in clinical trials for...   Read More

ICYMI: Orphan drug development brings unique challenges

By Gretta Stone  |    May 21, 2018
A new report from the Tufts Center for the Study of Drug Development finds that it takes 2.3 years, or 18 percent, longer to develop an orphan drug compared with medicines to treat more common...   Read More

New report portrays flourishing pipeline

By Gretta Stone  |    July 18, 2017
It’s an exciting time to be working in the biopharmaceutical industry. Almost every day new headlines highlight remarkable new advances in the fight against disease. Some have called this the golden...   Read More

Using setbacks as stepping stones in Alzheimer’s research

By Gretta Stone  |    August 3, 2016
For decades, biopharmaceutical researchers have worked tirelessly in the pursuit of new treatments and cures for the costly and devastating Alzheimer’s disease. Advancing treatments for Alzheimer’s...   Read More

New Study Illustrates Biopharmaceutical Industry’s Commitment to Personalized Medicine

By Gretta Stone  |    May 20, 2015
Potential personalized medicines represent 42 percent of drugs in the pipeline. This new finding, from a survey by the Tufts Center for the Study for Drug Development (CSDD), is remarkably high,...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates